DXCM vs SYRE
Dexcom vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | DXCM | SYRE |
|---|
| AI Score |
63
|
67
|
| Price |
$89.16
|
$93.00
|
| P/E Ratio |
35.16×
|
-54.69×
|
| ROE |
30.5%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
0.0%
|
| Debt / Equity |
0.53×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.4
|
57.5
|
| Beta |
1.41
|
3.026
|
| Expected Upside |
+2.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for DXCM versus SYRE.
SYRE leads by 4 points.
SYRE scores 67/100 (Buy) versus DXCM at 63/100 (Buy).
DXCM Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- RSI at 75 is in overbought territory — Technical
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical